Researchers found that a new drug called pemvidutide may significantly improve heart and metabolic health in people with a liver condition known as metabolic dysfunction-associated steatohepatitis (MASH). In a recent study, participants taking pemvidutide experienced notable reductions in triglycerides and cholesterol levels, along with weight loss and lower blood pressure. These changes are crucial because they address both the liver disease itself and the underlying metabolic issues that can lead to serious health risks.

For individuals looking to age well, these findings are particularly relevant. The study showed that those treated with pemvidutide lost an average of 7.5% of their body weight and saw reductions in waist circumference and blood pressure. This is significant for people with MASH, as cardiovascular disease is a leading cause of death in this population. Improvements in these metabolic markers can lead to better overall health and potentially longer life.

The evidence comes from a Phase 2b trial involving 212 participants over 48 weeks, which is a solid foundation but still considered early-stage research. While the results are promising, more extensive trials are needed to confirm the long-term safety and effectiveness of pemvidutide in a larger population. The next step is the PERFORMA Phase 3 trial, which aims to further evaluate the drug’s impact.

If you are interested in improving your metabolic health, consider discussing lifestyle changes with a healthcare provider. This may include a balanced diet, regular exercise, and weight management strategies, which can complement any potential benefits from emerging treatments like pemvidutide.

Source: globenewswire.com